Rise Advisors LLC Has $46,000 Stake in Edwards Lifesciences Co. (NYSE:EW)

Rise Advisors LLC grew its holdings in Edwards Lifesciences Co. (NYSE:EW) by 125.0% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 477 shares of the medical research company’s stock after purchasing an additional 265 shares during the quarter. Rise Advisors LLC’s holdings in Edwards Lifesciences were worth $46,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in EW. Martin Capital Advisors LLP grew its holdings in Edwards Lifesciences by 0.5% in the 4th quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company’s stock valued at $1,944,000 after buying an additional 128 shares during the last quarter. Legacy Wealth Asset Management LLC increased its position in Edwards Lifesciences by 0.8% during the fourth quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock worth $1,293,000 after acquiring an additional 134 shares during the period. Johnson Financial Group Inc. raised its stake in Edwards Lifesciences by 23.0% during the 4th quarter. Johnson Financial Group Inc. now owns 771 shares of the medical research company’s stock valued at $59,000 after purchasing an additional 144 shares during the last quarter. DMC Group LLC raised its stake in Edwards Lifesciences by 4.5% during the 4th quarter. DMC Group LLC now owns 3,561 shares of the medical research company’s stock valued at $272,000 after purchasing an additional 154 shares during the last quarter. Finally, Granite Harbor Advisors Inc. grew its position in Edwards Lifesciences by 4.2% in the 3rd quarter. Granite Harbor Advisors Inc. now owns 3,832 shares of the medical research company’s stock worth $265,000 after purchasing an additional 155 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Trading Up 0.4 %

Shares of EW opened at $88.86 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75. The company has a market cap of $53.55 billion, a price-to-earnings ratio of 38.30, a PEG ratio of 3.24 and a beta of 1.11. The stock has a fifty day moving average price of $87.45 and a two-hundred day moving average price of $84.28. Edwards Lifesciences Co. has a 52-week low of $60.57 and a 52-week high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. The business had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. Analysts predict that Edwards Lifesciences Co. will post 2.77 EPS for the current fiscal year.

Wall Street Analyst Weigh In

EW has been the subject of a number of research analyst reports. Oppenheimer upped their price objective on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a research report on Monday, March 18th. Barclays upped their target price on Edwards Lifesciences from $100.00 to $101.00 and gave the company an “overweight” rating in a research note on Tuesday, May 7th. Stifel Nicolaus lifted their price target on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the stock a “hold” rating in a research note on Friday, April 26th. Evercore ISI dropped their price objective on shares of Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating for the company in a research note on Friday, April 26th. Finally, Mizuho raised their price objective on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a report on Thursday, April 11th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average price target of $95.06.

Insiders Place Their Bets

In other news, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the sale, the vice president now directly owns 173,849 shares of the company’s stock, valued at $14,639,824.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Michael A. Mussallem sold 29,350 shares of Edwards Lifesciences stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $92.42, for a total value of $2,712,527.00. Following the completion of the sale, the director now directly owns 4,486 shares in the company, valued at $414,596.12. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the transaction, the vice president now owns 173,849 shares in the company, valued at $14,639,824.29. The disclosure for this sale can be found here. Over the last three months, insiders sold 127,104 shares of company stock valued at $11,267,464. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.